iSol

Based in South Korea, iSol specializes in robotics and AI solutions, focusing on developing innovative care robots for medical and caregiving applications to enhance patient quality of life. Founded in 2020 and headquartered in Gyeongsan, South Korea, iSol develops advanced robotics for healthcare. The company secured KRW 2 billion in venture funding from Oracle Venture Investment in January 2026, marking its first investment round and total raised amount. No previous company pivots or mergers have been noted.

iSol specializes in the development of innovative AI and robotics solutions that integrate advanced machine vision and human-centered design. The company’s core products include AI-powered care robots that assist in medical and caregiving settings, focusing on enhancing the quality of life for patients, the elderly, and children. Key offerings include non-invasive blood glucose monitoring devices and nursing robots designed to aid healthcare professionals by managing tasks such as patient mobility, medication management, and monitoring patient safety. These products are geared towards hospitals, nursing facilities, and home care environments, addressing the rising demand for efficient and compassionate care.

The geographical markets for these products include South Korea and potentially extend to other regions that have a growing need for healthcare automation and support solutions. iSol generates revenue through direct sales and partnerships related to its AI and robotics solutions. Transactions typically occur on a B2B basis, where healthcare facilities and institutions purchase or lease the company's products to enhance their service offerings. The pricing structure may include upfront costs for the acquisition of robots and devices, coupled with ongoing maintenance and service fees to ensure optimal performance.

This transactional model facilitates long-term relationships with clients, allowing for tailored solutions that meet specific operational needs. The company’s flagship products, such as the AI nursing robots and the non-invasive blood glucose monitoring devices, form the backbone of its revenue generation strategy, appealing to a range of healthcare providers looking to optimize care delivery. In January 2026, iSol raised KRW 2 billion in venture funding from Oracle Venture Investment. The company plans to leverage these funds to design and launch new products aimed at enhancing its robotics and AI solutions, as well as expanding into markets beyond South Korea, targeting regions with increasing healthcare automation needs by the end of 2026.